# US 11,896,598 B2 · Appetite suppressant compositions and methods thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,896,598 B2
- Document ID: US11896598B2
- Status: Granted
- Kind: B2
- Application number: 17/733,690
- Filed: 2022-04-29
- Published: 2022-08-11
- Granted: 2024-02-13
- Earliest claimed: 2020-03-03
- Assignees: Red Mountain Med Spa, LLC
- Applicants: Red Mountain Med Spa, LLC
- Inventors: Suzanne Bentz
- Web page: https://patentgrep.com/patent/US11896598B2

## CPC

- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/4808: {characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release (capsules filled with granules or microparticles A61K9/16; filled with microcapsules or coated microparticles A61K9/50; with mixture of different granules, microcapsules, (coated) microparticles A61K9/5084)}
- A61K 9/4866: {Organic macromolecular compounds}
- A61K 31/135: having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)}
- A61K 47/38: Cellulose; Derivatives thereof
- A61K 47/42: Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein (oligopeptides having up to five amino acids {A61K47/183}; polyamino acids A61K47/34)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

An appetite suppressant composition may comprise at least one anorectic active ingredient; at least one of a nutritive substance, a cofactor; and optionally, an excipient. The anorectic active ingredient may comprise any one of phentermine, phendimetrazine, diethylpropion, naltrexone, and bupropion. The nutritive substance may comprise a protein source such as bovine collagen. The cofactor may comprise a chromium or selenium salt. In various embodiments, the compositions herein are provided in an oral capsule dosage form for GI-tract administration of the AAI. A method of suppressing appetite in individuals in need thereof are described.

## Claims

### Claim 1

An appetite suppressant composition consisting essentially of:
from 12.0 wt. % to 18.0 wt. % phendimetrazine tartrate;
from 80.0 wt. % to 90.0 wt. % bovine collagen; and
from 0.05 wt. % to 0.10 wt. % chromium picolinate.

### Claim 2 (depends on 1)

A pharmaceutical dosage form for oral administration comprising: a capsule; and the appetite suppressant composition of claim 1 enclosed therein.

### Claim 3 (depends on 1)

A method of suppressing appetite in an individual, the method comprising orally administering to the individual in need thereof a therapeutically effective amount of the appetite suppressant composition of claim 1.

### Claim 4 (depends on 3)

The method of claim 3, wherein the therapeutically effective amount comprises orally administering up to 210 mg per day of the phendimetrazine tartrate.

### Claim 5 (depends on 3)

The method of claim 3, wherein the individual in need thereof is diagnosed overweight and obese.

### Claim 6 (depends on 1)

An appetite suppressant dosage form consisting essentially of:
250 mg to 300 mg of the composition of claim 1 as a loose powder; and
a dissolvable capsule encapsulating said composition.

### Claim 7

An appetite suppressant composition consisting essentially of:
from 6.0 wt. % to 12.0 wt. % diethylpropion-HCl, said diethylpropion-HCl including 1% tartaric acid;
from 50.0 wt. % to 58.0 wt. % bovine collagen; and
from 0.05 wt. % to 0.10 wt. % chromium picolinate.

### Claim 8 (depends on 7)

A pharmaceutical dosage form for oral administration comprising: a capsule; and the appetite suppressant composition of claim 7 enclosed therein.

### Claim 9 (depends on 7)

A method of suppressing appetite in an individual, the method comprising orally administering to the individual in need thereof a therapeutically effective amount of the appetite suppressant composition of claim 7.

### Claim 10 (depends on 9)

The method of claim 9, wherein the therapeutically effective amount comprises orally administering up to 150 mg per day of the diethylpropion-HCl.

### Claim 11 (depends on 9)

The method of claim 9, wherein the individual in need thereof is diagnosed overweight and obese.

### Claim 12 (depends on 7)

An appetite suppressant dosage form consisting essentially of:
250 mg to 300 mg of the composition of claim 7 as a loose powder; and
a dissolvable capsule encapsulating said composition.